Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $1.88 in the prior trading day, VYNE Therapeutics Inc (NASDAQ: VYNE) closed at $1.43, down -23.94%. In other words, the price has decreased by -$23.94 from its previous closing price. On the day, 1.66 million shares were traded.
Ratios:
Our goal is to gain a better understanding of VYNE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.35 and its Current Ratio is at 4.35. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on November 18, 2024, initiated with a Buy rating and assigned the stock a target price of $8.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 15 ’25 when LEPORE PATRICK G bought 15,000 shares for $2.92 per share. The transaction valued at 43,800 led to the insider holds 51,472 shares of the business.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 43.50 while its Price-to-Book (P/B) ratio in mrq is 0.41.
Stock Price History:
Over the past 52 weeks, VYNE has reached a high of $4.30, while it has fallen to a 52-week low of $1.44. The 50-Day Moving Average of the stock is -27.53%, while the 200-Day Moving Average is calculated to be -37.18%.
Shares Statistics:
A total of 14.83M shares are outstanding, with a floating share count of 12.68M. Insiders hold about 16.66% of the company’s shares, while institutions hold 47.99% stake in the company.
